Global Biosimilar Monoclonal Antibodies (mAbs) Market Opportunities, Challenges, Strategies & Forecasts
Global Biosimilar Monoclonal Antibodies (mAbs) Market Opportunities, Challenges, Strategies & Forecasts
The Biosimilar Monoclonal Antibodies (mAbs) Market report highlights technological advancements, investment opportunities, and regulatory frameworks shaping the industry landscape through 2030.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
This report studies the Biosimilar Monoclonal Antibodies (mAbs) market, covering market size for segment by type (Infliximab, Rituximab, etc.), by application (Oncology, Autoimmune Disease, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy’s, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).
This report provides detailed historical analysis of global market for Biosimilar Monoclonal Antibodies (mAbs) from 2016-2021, and provides extensive market forecasts from 2022-2030 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Biosimilar Monoclonal Antibodies (mAbs) market.
Moreover, the impact of COVID-19 is also concerned. Since outbreak in December 2019, the COVID-19 virus has spread to all around the world and caused huge losses of lives and economy, and the global manufacturing, tourism and financial markets have been hit hard, while the online market/industry increase. Fortunately, with the development of vaccine and other effort by global governments and organizations, the negative impact of COVID-19 is expected to subside and the global economy is expected to recover.
This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Leading players of Biosimilar Monoclonal Antibodies (mAbs) including:
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Biocon
Market split by Type, can be divided into:
Infliximab
Rituximab
Trastuzumab
Adalimumab
Others
Market split by Application, can be divided into:
Oncology
Autoimmune Disease
Others
Market split by Sales Channel, can be divided into:
Direct Channel
Distribution Channel
Market segment by Region/Country including:
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Spain etc.)
Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
South America (Brazil, Argentina and Colombia etc.)
Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)
Key Questions Answered in Report
Which is the most lucrative market
Which factors will impact the growth of the market
How will changing trends impact the strategies of market players
How can market players capture the low-hanging opportunities across regions
Which companies are leading the industry
What are the winning strategies of stakeholders in the market
Chapter 1 Biosimilar Monoclonal Antibodies (mAbs) Market Overview
1.1 Biosimilar Monoclonal Antibodies (mAbs) Definition
1.2 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Status and Outlook (2016-2030)
1.3 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Comparison by Region (2016-2030)
1.4 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Comparison by Type (2016-2030)
1.5 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Comparison by Application (2016-2030)
1.6 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Comparison by Sales Channel (2016-2030)
1.7 Biosimilar Monoclonal Antibodies (mAbs) Market Dynamics (COVID-19 Impacts)
1.7.1 Market Drivers/Opportunities
1.7.2 Market Challenges/Risks
1.7.3 Market News (Mergers/Acquisitions/Expansion)
1.7.4 COVID-19 Impacts
1.7.5 Post-Strategies of COVID-19
Chapter 2 Biosimilar Monoclonal Antibodies (mAbs) Market Segment Analysis by Player
2.1 Global Biosimilar Monoclonal Antibodies (mAbs) Sales and Market Share by Player (2019-2021)
2.2 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Player (2019-2021)
2.3 Global Biosimilar Monoclonal Antibodies (mAbs) Average Price by Player (2019-2021)
2.4 Players Competition Situation & Trends
2.5 Conclusion of Segment by Player
Chapter 3 Biosimilar Monoclonal Antibodies (mAbs) Market Segment Analysis by Type
3.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market by Type
3.1.1 Infliximab
3.1.2 Rituximab
3.1.3 Trastuzumab
3.1.4 Adalimumab
3.1.5 Others
3.2 Global Biosimilar Monoclonal Antibodies (mAbs) Sales and Market Share by Type (2016-2021)
3.3 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Type (2016-2021)
3.4 Global Biosimilar Monoclonal Antibodies (mAbs) Average Price by Type (2016-2021)
3.5 Leading Players of Biosimilar Monoclonal Antibodies (mAbs) by Type in 2021
3.6 Conclusion of Segment by Type
Chapter 4 Biosimilar Monoclonal Antibodies (mAbs) Market Segment Analysis by Application
4.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market by Application
4.1.1 Oncology
4.1.2 Autoimmune Disease
4.1.3 Others
4.2 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Application (2016-2021)
4.3 Leading Consumers of Biosimilar Monoclonal Antibodies (mAbs) by Application in 2021
4.4 Conclusion of Segment by Application
Chapter 5 Biosimilar Monoclonal Antibodies (mAbs) Market Segment Analysis by Sales Channel
5.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market by Sales Channel
5.1.1 Direct Channel
5.1.2 Distribution Channel
5.2 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Sales Channel (2016-2021)
5.3 Leading Distributors/Dealers of Biosimilar Monoclonal Antibodies (mAbs) by Sales Channel in 2021
5.4 Conclusion of Segment by Sales Channel
Chapter 6 Biosimilar Monoclonal Antibodies (mAbs) Market Segment Analysis by Region
6.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR by Region (2016-2030)
6.2 Global Biosimilar Monoclonal Antibodies (mAbs) Sales and Market Share by Region (2016-2021)
6.3 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Region (2016-2021)
6.4 North America
6.4.1 North America Market by Country
6.4.2 North America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.4.3 North America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.4.4 United States
6.4.5 Canada
6.4.6 Mexico
6.5 Europe
6.5.1 Europe Market by Country
6.5.2 Europe Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.5.3 Europe Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.5.4 Germany
6.5.5 UK
6.5.6 France
6.5.7 Italy
6.5.8 Russia
6.5.9 Spain
6.6 Asia-Pacific
6.6.1 Asia-Pacific Market by Country
6.6.2 Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.6.3 Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.6.4 China
6.6.5 Japan
6.6.6 Korea
6.6.7 India
6.6.8 Southeast Asia
6.6.9 Australia
6.7 South America
6.7.1 South America Market by Country
6.7.2 South America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.7.3 South America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.7.4 Brazil
6.7.5 Argentina
6.7.6 Colombia
6.8 Middle East & Africa
6.8.1 Middle East & Africa Market by Country
6.8.2 Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.8.3 Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.8.4 UAE
6.8.5 Saudi Arabia
6.8.6 South Africa
6.9 Conclusion of Segment by Region
Chapter 7 Profile of Leading Biosimilar Monoclonal Antibodies (mAbs) Players
7.1 Celltrion
7.1.1 Company Snapshot
7.1.2 Product/Service Offered
7.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)
7.2 Pfizer (Hospira)
7.3 3SBIO
7.4 Novartis (Sandoz)
7.5 Dr Reddy’s
7.6 Celgen Biopharma
7.7 Cadila Healthcare
7.8 Hisun Pharma
7.9 Torrent Pharmaceuticals
7.10 Biocon
Chapter 8 Upstream and Downstream Analysis of Biosimilar Monoclonal Antibodies (mAbs)
8.1 Industrial Chain of Biosimilar Monoclonal Antibodies (mAbs)
8.2 Upstream of Biosimilar Monoclonal Antibodies (mAbs)
8.3 Downstream of Biosimilar Monoclonal Antibodies (mAbs)
Chapter 9 Development Trend of Biosimilar Monoclonal Antibodies (mAbs) (2022-2030)
9.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size (Sales and Revenue) Forecast (2022-2030)
9.2 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Region (2022-2030)
9.3 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Type (2022-2030)
9.4 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Application (2022-2030)
9.5 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Sales Channel (2022-2030)
Chapter 10 Appendix
10.1 Research Methodology
10.2 Data Sources
10.3 Disclaimer
10.4 Analysts Certification
List of Tables and Figures
Figure Biosimilar Monoclonal Antibodies (mAbs) Example
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) Status and Outlook (2016-2030)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) Comparison by Region (2016-2030)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) Comparison by Type (2016-2030)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) Comparison by Application (2016-2030)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) Comparison by Sales Channel (2016-2030)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Sales by Player (2019-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Player (2019-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Player in 2021
Table Global Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) by Player (2019-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Player (2019-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Player in 2021
Table Global Biosimilar Monoclonal Antibodies (mAbs) Average Price by Player (2019-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Average Price by Player in 2021
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Players Competition Situation – Top 5 Players’ Revenue Market Share in 2019
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Players Competition Trends – Top 5 Players’ Revenue Market Share in 2021
Figure Example of Infliximab
Figure Global Infliximab Revenue (Million $) and Growth Rate (2016-2021)
Figure Example of Rituximab
Figure Global Rituximab Revenue (Million $) and Growth Rate (2016-2021)
Figure Example of Trastuzumab
Figure Global Trastuzumab Revenue (Million $) and Growth Rate (2016-2021)
Figure Example of Adalimumab
Figure Global Adalimumab Revenue (Million $) and Growth Rate (2016-2021)
Figure Example of Others
Figure Global Others Revenue (Million $) and Growth Rate (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Sales by Type (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Type (2016-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Type in 2021
Table Global Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) by Type (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Type (2016-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Type in 2021
Table Global Biosimilar Monoclonal Antibodies (mAbs) Average Price by Type (2016-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Average Price by Type in 2021
Table Leading Players of Biosimilar Monoclonal Antibodies (mAbs) by Type in 2021
Figure Example of Oncology
Figure Global Biosimilar Monoclonal Antibodies (mAbs) for Oncology Revenue (Million $) and Growth Rate (2016-2021)
Figure Example of Autoimmune Disease
Figure Global Biosimilar Monoclonal Antibodies (mAbs) for Autoimmune Disease Revenue (Million $) and Growth Rate (2016-2021)
Figure Example of Others
Figure Global Biosimilar Monoclonal Antibodies (mAbs) for Others Revenue (Million $) and Growth Rate (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Sales by Application (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Application (2016-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Application in 2021
Table Leading Consumers of Biosimilar Monoclonal Antibodies (mAbs) by Application in 2021
Figure Example of Direct Channel
Figure Global Biosimilar Monoclonal Antibodies (mAbs) for Direct Channel Revenue (Million $) and Growth Rate (2016-2021)
Figure Example of Distribution Channel
Figure Global Biosimilar Monoclonal Antibodies (mAbs) for Distribution Channel Revenue (Million $) and Growth Rate (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Revenue by Sales Channel (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Sales Channel (2016-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Sales Channel in 2021
Table Leading Distributors/Dealers of Biosimilar Monoclonal Antibodies (mAbs) by Sales Channel in 2021
Table Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR by Region (2016-2030)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Sales by Region (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Region (2016-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Region in 2021
Table Global Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) by Region (2016-2021)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Region (2016-2021)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Region in 2021
Table North America Biosimilar Monoclonal Antibodies (mAbs) Sales by Country (2016-2021)
Figure North America Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Country (2016-2021)
Table North America Biosimilar Monoclonal Antibodies (mAbs) Revenue by Country (2016-2021)
Figure North America Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Country (2016-2021)
Figure North America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type in 2021
Figure North America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application in 2021
Figure United States Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure United States Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Canada Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Canada Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Mexico Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Mexico Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Table Europe Biosimilar Monoclonal Antibodies (mAbs) Sales by Country (2016-2021)
Figure Europe Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Country (2016-2021)
Table Europe Biosimilar Monoclonal Antibodies (mAbs) Revenue by Country (2016-2021)
Figure Europe Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Country (2016-2021)
Figure Europe Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type in 2021
Figure Europe Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application in 2021
Figure Germany Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Germany Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure UK Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure UK Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure France Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure France Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Italy Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Italy Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Russia Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Russia Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Spain Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Spain Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Table Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Sales by Country (2016-2021)
Figure Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Country (2016-2021)
Table Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Revenue by Country (2016-2021)
Figure Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Country (2016-2021)
Figure Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type in 2021
Figure Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application in 2021
Figure China Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure China Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Japan Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Japan Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Korea Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Korea Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure India Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure India Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Southeast Asia Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Southeast Asia Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Australia Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Australia Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Table South America Biosimilar Monoclonal Antibodies (mAbs) Sales by Country (2016-2021)
Figure South America Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Country (2016-2021)
Table South America Biosimilar Monoclonal Antibodies (mAbs) Revenue by Country (2016-2021)
Figure South America Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Country (2016-2021)
Figure South America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type in 2021
Figure South America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application in 2021
Figure Brazil Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Brazil Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Argentina Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Argentina Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Colombia Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Colombia Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Table Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Sales by Country (2016-2021)
Figure Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Sales Market Share by Country (2016-2021)
Table Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Revenue by Country (2016-2021)
Figure Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Revenue Market Share by Country (2016-2021)
Figure Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type in 2021
Figure Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application in 2021
Figure UAE Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure UAE Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure Saudi Arabia Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure Saudi Arabia Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Figure South Africa Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate (2016-2021)
Figure South Africa Biosimilar Monoclonal Antibodies (mAbs) Revenue (Million $) and Growth Rate (2016-2021)
Table Company Snapshot of Celltrion
Table Biosimilar Monoclonal Antibodies (mAbs) Introduction of Celltrion
Table Biosimilar Monoclonal Antibodies (mAbs) Sales, Price, Revenue, Gross Margin and Market Share of Celltrion (2019-2021)
Table Industrial Chain of Biosimilar Monoclonal Antibodies (mAbs)
Table Manufacturing Cost Structure of Biosimilar Monoclonal Antibodies (mAbs)
Table General Manufacturing Process of Biosimilar Monoclonal Antibodies (mAbs)
Table Leading Distributors/Dealers of Biosimilar Monoclonal Antibodies (mAbs)
Table Leading Consumers of Biosimilar Monoclonal Antibodies (mAbs)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Sales and Growth Rate Forecast (2022-2030)
Figure Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Growth Rate Forecast (2022-2030)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Region (2022-2030)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Type (2022-2030)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Application (2022-2030)
Table Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Sales Channel (2022-2030)
Research Methodology:
Biosimilar Monoclonal Antibodies (mAbs) Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|